← 產業報告目錄

Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-09-15頁數 564報告編號 BT4780

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The immunohistochemistry market is expected to reach USD 5.14 billion in 2030 from USD 3.55 billion in 2024, at a CAGR of 7.6% during the forecast period. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology to develop personalized medicine further support the expansion of the market. The histological stain segment accounted for the largest share of the immunohistochemistry reagents segment in 2024. The market is segmented into histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents, diluents, organic solvents, proteolytic enzymes, and other reagents. In 2024, the histological stains segment accounted for the largest share of the immunohistochemistry market. This is due to their primary application being in immunohistochemistry, a powerful technique where stains are used to visualize and differentiate specific cellular components, proteins, and structures within tissue samples by leveraging antigen-antibody interactions. This allows for the precise localization of biomarkers critical for diagnosis and research. Furthermore, the utility of histological stains is expanding through advanced techniques like multiplex staining, also known as multiple staining. This method employs several stains simultaneously to detect multiple targets within a single tissue section. This is particularly valuable in fields like immuno-oncology as it conserves precious patient samples while providing a comprehensive view of the complex tumor microenvironment. A major driver for this market remains its pivotal function in cancer diagnosis, where pathologists use these stains to distinguish between normal and abnormal tissue morphology, thereby determining tumor grade and type. In 2024, by application, the research applications segment accounted for the second-largest share of the market. The immunohistochemistry market is segmented into diagnostic applications, research applications, and forensic applications. In 2024, the research applications segment accounted for the second-largest share of the immunohistochemistry market. IHC technology is a cornerstone of modern biomedical investigation, particularly in anti-tumor drug development and biomarker discovery. It provides researchers with an unparalleled ability to visualize the expression and precise subcellular location of specific proteins within the contextual architecture of tissue. This is fundamental to understanding the complex cellular mechanisms that underpin cancer and other diseases. For instance, in the exploration of the cancer proteome, IHC is instrumental for validating new drug targets identified through genomic or proteomic screening, confirming their presence and relevance in actual tumor tissues. The role of IHC in research extends across numerous scientific disciplines. In developmental biology and embryological studies, it allows for mapping key regulatory proteins during different stages of development, offering insights crucial for understanding morphogenesis and congenital disorders. Similarly, in stem cell research, IHC is used to monitor markers of proliferation and differentiation, providing essential data on stem cell behavior and therapeutic potential. The continuous investment in R&D by pharmaceutical and biotechnology companies, coupled with the global push towards personalized medicine, ensures that the research application segment will remain a dynamic and expanding component of the immunohistochemistry market. . In 2024, North America accounted for the largest share of the immunohistochemistry market. North America accounted for the largest share of the immunohistochemistry market in 2024. This leadership position is underpinned by various factors, including the region's highly advanced healthcare infrastructure, substantial healthcare expenditure, and the robust presence of key market players and leading research institutions. The US, in particular, serves as the primary driver of this growth, fueled by a high prevalence of chronic diseases, most notably cancer. The significant and rising incidence of various cancers necessitates sophisticated and accurate diagnostic tools, with IHC being a cornerstone of modern pathology for tumor classification and biomarker analysis. Furthermore, the region benefits from extensive government and private funding for biomedical research and development, which accelerates the adoption of innovative IHC technologies and automated platforms. Favorable reimbursement policies and a high level of awareness among clinicians and patients regarding advanced diagnostic options also contribute to the market's expansion. The strong regulatory framework, while stringent, ensures the quality and reliability of IHC products, fostering trust and widespread use in both clinical diagnostics and the burgeoning pharmaceutical and biotechnology research sectors, solidifying the preeminent standing of North America in the global IHC landscape. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40% • By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25% • By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2% F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), PHC Holdings Corporation (Japan), Enzo Biochem Inc. (US), Sino Biological, Inc. (China), OriGene Technologies, Inc. (US), Cell Signaling Technology, Inc. (US), Bio SB (US), Miltenyi Biotec (Germany), Sakura Finetek (US), EagleBio (US), Biocare Medical LLC (US), Elabscience BioInnovation Inc. (US), Bio-Genex (US), Diagnostic BioSystems Inc. (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals, Inc. (US), and CANDOR Bioscience GmbH (Germany) are some of the key companies offering immunohistochemistry products. Research Coverage This research report categorizes the immunohistochemistry market by Product & Service, Product (Antibodies [Primary antibodies, secondary antibodies], [Clonality {Monoclonal, Polyclonal}], [Regulatory Class {Class I/II Assay Antibodies, Class III Assay Antibodies}], Reagents [blocking sera and reagents, chromogenic substrates, fixation reagents, diluents, organic solvents, proteolytic enzymes, other reagents], Kits [Human Immunohistochemistry Kits, Animal Immunohistochemistry Kits], Instruments & Software (IHC Stainers), [Sample Preparation Instruments {Tissue Processors, Microtomes, Other Sample Preparation Instruments}], (Image Analysis Instruments), Service, Application (Diagnostic Applications [Cancer, Infectious Diseases, Nephrological Diseases, Autoimmune Diseases, Neurological Diseases, Other Diseases] Research Applications [Drug Development and testing, Other Research Applications], Forensic Applications}, End User for Product (Hospitals & Diagnostic Laboratories, Academic & Research Institutes and Contract Research Organizations, Other End Users), End User for Service (Pharmaceutical & Biotechnology Companies and Academic Institutions) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the immunohistochemistry market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the immunohistochemistry market. This report covers a competitive analysis of top players and upcoming startups in the immunohistochemistry market ecosystem. The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the immunohistochemistry market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the immunohistochemistry market. This report covers the competitive analysis of upcoming startups in the immunohistochemistry market ecosystem. Key Benefits of Buying the Report This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies. The report provides insights on the following pointers: Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization) • Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market. • Market Development: Comprehensive information about lucrative markets – the report analyses the Immunohistochemistry market across varied regions. • Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
目錄 Table of Contents
1 INTRODUCTION 51 1.1 STUDY OBJECTIVES 51 1.2 MARKET DEFINITION 51 1.3 STUDY SCOPE 52 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 52 1.3.2 INCLUSIONS & EXCLUSIONS 53 1.3.3 YEARS CONSIDERED 54 1.3.4 CURRENCY CONSIDERED 55 1.4 STAKEHOLDERS 55 1.5 SUMMARY OF CHANGES 55 2 RESEARCH METHODOLOGY 57 2.1 RESEARCH DATA 57 2.1.1 SECONDARY DATA 58 2.1.1.1 Key sources of secondary data 58 2.1.1.2 Key objectives of secondary research 58 2.1.2 PRIMARY DATA 59 2.1.2.1 Breakdown of primaries 59 2.1.2.2 Key objectives of primary research 60 2.2 MARKET SIZE ESTIMATION 60 2.2.1 GLOBAL MARKET SIZE ESTIMATION 60 2.2.1.1 Revenue share analysis (bottom-up approach) 61 2.2.1.2 Secondary data 62 2.2.1.3 Primary interviews and MnM repository analysis 62 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 63 2.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 63 2.3 MARKET GROWTH RATE PROJECTION 65 2.4 DATA TRIANGULATION 67 2.5 STUDY ASSUMPTIONS 68 2.6 RESEARCH LIMITATIONS 69 2.7 RISK ANALYSIS 69 3 EXECUTIVE SUMMARY 70 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 74 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS 74 3.3 DISRUPTIVE TRENDS SHAPING IMMUNOHISTOCHEMISTRY MARKET 75 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 75 3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 76 4 PREMIUM INSIGHTS 77 4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 77 4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY, 2024 78 4.3 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET SHARE, BY END USER, 2024 78 4.4 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79 4.5 UNMET NEEDS & WHITE SPACES 79 4.6 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 80 4.7 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 80 4.8 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 81 4.9 VC/PRIVATE EQUITY INVESTMENT TRENDS 81 4.10 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 82 5 MARKET OVERVIEW 83 5.1 INTRODUCTION 83 5.2 MARKET DYNAMICS 83 5.2.1 DRIVERS 84 5.2.1.1 Increasing adoption of companion diagnostics 84 5.2.1.2 Favorable reimbursement coverage for immunohistochemistry tests 85 5.2.1.3 Growing focus on digital pathology 86 5.2.2 RESTRAINTS 88 5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research 88 5.2.2.2 Highly consolidated global market 88 5.2.3 OPPORTUNITIES 89 5.2.3.1 Rising demand for precision/personalized medicines 89 5.2.3.2 High growth opportunities in emerging economies 90 5.2.3.3 Integration of AI in immunohistochemistry 91 5.2.4 CHALLENGES 91 5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables 91 5.2.4.2 Lack of preanalytical and analytical method standardization 91 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 92 5.4 PRICING ANALYSIS 93 5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY KEY PLAYER, 2022–2024 93 5.4.2 AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2022–2024 95 5.5 TECHNOLOGY ANALYSIS 98 5.5.1 KEY TECHNOLOGIES 98 5.5.1.1 Automated immunohistochemistry systems 98 5.5.1.2 Multiplex immunohistochemistry 98   5.5.2 COMPLEMENTARY TECHNOLOGIES 99 5.5.2.1 Chromogenic detection 99 5.5.2.2 Fluorescent detection 99 5.5.3 ADJACENT TECHNOLOGIES 99 5.5.3.1 In situ hybridization 99 5.6 PATENT ANALYSIS 100 5.6.1 METHODOLOGY 100 5.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 100 5.6.3 LIST OF KEY PATENTS 102 5.7 TRADE ANALYSIS 103 5.7.1 IMPORT DATA FOR HS CODE 3822.00, 2020–2024 103 5.7.2 EXPORT DATA FOR HS CODE 3822.00, 2020–2024 104 5.8 VALUE CHAIN ANALYSIS 104 5.9 ECOSYSTEM ANALYSIS 106 5.9.1 ROLE IN ECOSYSTEM 108 5.10 PORTER’S FIVE FORCES ANALYSIS 108 5.10.1 INTENSITY OF COMPETITIVE RIVALRY 110 5.10.2 BARGAINING POWER OF SUPPLIERS 110 5.10.3 BARGAINING POWER OF BUYERS 110 5.10.4 THREAT OF SUBSTITUTES 110 5.10.5 THREAT OF NEW ENTRANTS 110 5.11 KEY STAKEHOLDERS & BUYING CRITERIA 111 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 111 5.11.2 KEY BUYING CRITERIA 112 5.12 TARIFF & REGULATORY ANALYSIS 114 5.12.1 TARIFF DATA ANALYSIS 114 5.12.2 REGULATORY LANDSCAPE 115 5.12.2.1 North America 115 5.12.2.1.1 US 115 5.12.2.1.2 Canada 117 5.12.2.2 Europe 117 5.12.2.3 Asia Pacific 119 5.12.2.3.1 Japan 119 5.12.2.3.2 China 120 5.12.2.3.3 India 120 5.12.2.4 Latin America 121 5.12.2.4.1 Brazil 121 5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 122 5.13 KEY CONFERENCES & EVENTS, 2025–2026 125 5.14 INVESTMENT & FUNDING SCENARIO 126 5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET 127 5.16 IMPACT OF 2025 US TARIFF ON IMMUNOHISTOCHEMISTRY MARKET 130 5.16.1 KEY TARIFF RATES 130 5.16.2 PRICE IMPACT ANALYSIS 131 5.16.3 IMPACT ON KEY COUNTRIES/REGIONS 132 5.16.3.1 North America 132 5.16.3.1.1 US 132 5.16.3.2 Europe 132 5.16.3.3 Asia Pacific 132 5.16.3.4 Rest of the World 133 5.16.4 IMPACT ON END-USE INDUSTRIES 133 5.16.4.1 Pharmaceutical & biopharmaceutical companies 133 5.16.4.2 Hospitals & clinics 133 5.16.4.3 Academic & research institutes 133 5.16.4.4 Contract research organizations 134 6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING 135 6.1 INTRODUCTION 136 6.2 ANTIBODIES 136 6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE 139 6.2.1.1 Primary antibodies 139 6.2.1.1.1 Increasing adoption of targeted immunotherapy and custom antibody development to drive segment 139 6.2.1.2 Secondary antibodies 142 6.2.1.2.1 Better signal amplification and easier manufacturing process to fuel segment growth 142 6.2.2 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY 146 6.2.2.1 Monoclonal antibodies 149 6.2.2.1.1 Increased applications in cancer diagnostics to support segment growth 149 6.2.2.2 Polyclonal antibodies 152 6.2.2.2.1 Better sensitivity and higher resistance to changes in antigen conformation to augment segment growth 152 6.2.3 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS 154 6.2.3.1 Class I/II assay antibodies 155 6.2.3.1.1 Focus on precision medicine and standardized reagents to favor segment growth 155 6.2.3.2 Class III assay antibodies 158 6.2.3.2.1 Expansion of targeted therapies to augment segment growth 158   6.3 REAGENTS 161 6.3.1 BLOCKING SERA & REAGENTS 164 6.3.1.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption 164 6.3.2 CHROMOGENIC SUBSTRATES 167 6.3.2.1 Rapid detection and faster diagnosis to propel segment growth 167 6.3.3 FIXATION REAGENTS 170 6.3.3.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption 170 6.3.4 ORGANIC SOLVENTS 173 6.3.4.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market 173 6.3.5 PROTEOLYTIC ENZYMES 175 6.3.5.1 Proteolytic enzymes to improve accessibility of target antibodies and DNA 175 6.3.6 DILUENTS 178 6.3.6.1 Need for reducing non-specific background staining during immunostaining to aid segment growth 178 6.3.7 OTHER REAGENTS 181 6.4 KITS 184 6.4.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 187 6.4.1.1 Increasing focus on cancer research to fuel segment growth 187 6.4.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 190 6.4.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth 190 6.5 INSTRUMENTS & SOFTWARE 193 6.5.1 IHC STAINERS 196 6.5.1.1 Increased availability of automated IHC stainers to fuel segment growth 196 6.5.2 SAMPLE PREPARATION INSTRUMENTS 199 6.5.2.1 Tissue processors 202 6.5.2.1.1 Rising biopsy volumes and increasing workflow automation to fuel segment growth 202 6.5.2.2 Microtomes 204 6.5.2.2.1 High precision demand and increased workforce challenges to aid segment growth 204 6.5.2.3 Other sample preparation instruments 207 6.5.3 IMAGE ANALYSIS INSTRUMENTS 210 6.5.3.1 Escalating demand for objective and reproducible quantification of IHC-stained tissue to boost segment growth 210 6.6 SERVICES 213 6.6.1 INCREASED COMPLEXITY OF BIOMARKER REQUIREMENTS AND EXPANSION OF GLOBAL CLINICAL TRIALS TO AID MARKET GROWTH 213   7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 216 7.1 INTRODUCTION 217 7.2 DIAGNOSTIC APPLICATIONS 217 7.2.1 CANCER 220 7.2.1.1 Automation, AI-enhanced quantitation, and multiplexing to accelerate global cancer IHC adoption 220 7.2.2 INFECTIOUS DISEASES 223 7.2.2.1 Multiplex pathogen panels, automation, and AI-driven imaging to boost market growth 223 7.2.3 AUTOIMMUNE DISEASES 226 7.2.3.1 Focus on AI-powered multiplex imaging and automated analysis to propel market growth 226 7.2.4 NEPHROLOGICAL DISEASES 229 7.2.4.1 Better understanding of novel renal biomarkers and virtual multiplexing to accelerate market growth 229 7.2.5 NEUROLOGICAL DISEASES 232 7.2.5.1 Advances in neuroimmunopathology, novel biomarker discovery, multiplexing, and AI-supported image analysis to drive market 232 7.2.6 OTHER DIAGNOSTIC APPLICATIONS 235 7.3 RESEARCH APPLICATIONS 238 7.3.1 DRUG DEVELOPMENT & TESTING 241 7.3.1.1 AI-enabled quantitation, regulatory support, and organ-on-chip integration to propel growth in drug development 241 7.3.2 OTHER RESEARCH APPLICATIONS 244 7.4 FORENSIC APPLICATIONS 247 7.4.1 ADVANCEMENTS IN VALIDATED INJURY AND DEATH MARKERS WITH IHC INTEGRATION IN FORENSIC IMAGING TO DRIVE MARKET 247 8 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER 250 8.1 INTRODUCTION 251 8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 251 8.2.1 EXPANSION OF DIAGNOSTIC INFRASTRUCTURE AND DIGITAL AUTOMATION TO DRIVE GLOBAL MARKET GROWTH 251 8.3 ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS 254 8.3.1 INNOVATION IN MULTIPLEX AND AI-ENABLED IMMUNOHISTOCHEMISTRY TO FUEL GLOBAL MARKET EXPANSION 254 8.4 OTHER END USERS 258 9 IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER 261 9.1 INTRODUCTION 262 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 262 9.2.1 INTEGRATION OF MULTIPLEX IHC SERVICES WITH REGULATORY-CLEARED WORKFLOWS TO AUGMENT MARKET GROWTH 262   9.3 ACADEMIC INSTITUTIONS 265 9.3.1 ADOPTION OF MULTIPLEX SPATIAL IMMUNOHISTOCHEMISTRY AND DIGITAL PATHOLOGY TO BOOST MARKET GROWTH 265 10 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 269 10.1 INTRODUCTION 270 10.2 NORTH AMERICA 270 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 277 10.2.2 US 278 10.2.2.1 US to dominate North American immunohistochemistry market during forecast period 278 10.2.3 CANADA 283 10.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth 283 10.3 EUROPE 288 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 293 10.3.2 GERMANY 294 10.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market 294 10.3.3 UK 300 10.3.3.1 Rising prevalence of cancer and increasing government funding in healthcare research to augment market growth 300 10.3.4 FRANCE 305 10.3.4.1 Increased research in cancer diagnosis and treatment to support market growth 305 10.3.5 ITALY 310 10.3.5.1 Advanced healthcare infrastructure and high geriatric population to fuel market growth 310 10.3.6 SPAIN 315 10.3.6.1 Increased demand for personalized medicines to boost adoption of immunohistochemistry products 315 10.3.7 REST OF EUROPE 320 10.4 ASIA PACIFIC 325 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 331 10.4.2 CHINA 333 10.4.2.1 Rising healthcare investments and increasing cancer burden to spur market growth 333 10.4.3 JAPAN 338 10.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth 338 10.4.4 INDIA 343 10.4.4.1 Need for high-end pathology and diagnostic services to propel market growth 343 10.4.5 AUSTRALIA 348 10.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth 348 10.4.6 SOUTH KOREA 353 10.4.6.1 Focus on precision healthcare and personalized medicines to drive market 353 10.4.7 REST OF ASIA PACIFIC 358 10.5 LATIN AMERICA 363 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 368 10.5.2 BRAZIL 369 10.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth 369 10.5.3 MEXICO 374 10.5.3.1 Increasing research initiatives and rising cancer cases to drive market 374 10.5.4 REST OF LATIN AMERICA 379 10.6 MIDDLE EAST 384 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 389 10.6.2 GCC COUNTRIES 390 10.6.2.1 Kingdom of Saudi Arabia 395 10.6.2.1.1 Growing cancer burden and increasing focus on oncology-based research programs to augment market growth 395 10.6.2.2 UAE 400 10.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth 400 10.6.2.3 Rest of GCC Countries 405 10.6.3 REST OF MIDDLE EAST 410 10.7 AFRICA 415 10.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET 415 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 420 11 COMPETITIVE LANDSCAPE 422 11.1 INTRODUCTION 422 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 422 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET 422 11.3 REVENUE ANALYSIS, 2020–2024 424 11.4 MARKET SHARE ANALYSIS, 2024 425 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 427 11.5.1 STARS 427 11.5.2 EMERGING LEADERS 427 11.5.3 PERVASIVE PLAYERS 427 11.5.4 PARTICIPANTS 428 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 429 11.5.5.1 Company footprint 429 11.5.5.2 Region footprint 429 11.5.5.3 Offering footprint 430 11.5.5.4 Application footprint 431 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 432 11.6.1 PROGRESSIVE COMPANIES 432 11.6.2 RESPONSIVE COMPANIES 432 11.6.3 DYNAMIC COMPANIES 432 11.6.4 STARTING BLOCKS 432 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 434 11.6.5.1 Detailed list of key startups/SMEs 434 11.6.5.2 Competitive benchmarking of key startups/SMEs 435 11.7 COMPANY VALUATION & FINANCIAL METRICS 436 11.7.1 FINANCIAL METRICS 436 11.7.2 COMPANY VALUATION 436 11.8 BRAND/PRODUCT COMPARISON 437 11.9 COMPETITIVE SCENARIO 438 11.9.1 PRODUCT APPROVALS 438 11.9.2 DEALS 439 11.9.3 EXPANSIONS 439 11.9.4 OTHER DEVELOPMENTS 440 12 COMPANY PROFILES 441 12.1 KEY PLAYERS 441 12.1.1 F. HOFFMANN-LA ROCHE LTD. 441 12.1.1.1 Business overview 441 12.1.1.2 Products/Services offered 442 12.1.1.3 Recent developments 446 12.1.1.3.1 Product launches and approvals 446 12.1.1.4 MnM view 448 12.1.1.4.1 Key strengths 448 12.1.1.4.2 Strategic choices 448 12.1.1.4.3 Weaknesses & competitive threats 449 12.1.2 DANAHER CORPORATION 450 12.1.2.1 Business overview 450 12.1.2.2 Products/Services offered 451 12.1.2.3 Recent developments 455 12.1.2.3.1 Product launches and approvals 455 12.1.2.3.2 Deals 456 12.1.2.4 MnM view 456 12.1.2.4.1 Key strengths 456 12.1.2.4.2 Strategic choices 456 12.1.2.4.3 Weaknesses & competitive threats 456   12.1.3 AGILENT TECHNOLOGIES, INC. 457 12.1.3.1 Business overview 457 12.1.3.2 Products/Services offered 458 12.1.3.3 Recent developments 462 12.1.3.3.1 Product approvals 462 12.1.3.3.2 Deals 463 12.1.3.3.3 Expansions 463 12.1.3.4 MnM view 464 12.1.3.4.1 Key strengths 464 12.1.3.4.2 Strategic choices 464 12.1.3.4.3 Weaknesses & competitive threats 464 12.1.4 PHC HOLDINGS CORPORATION 465 12.1.4.1 Business overview 465 12.1.4.2 Products/Services offered 466 12.1.4.3 Recent developments 471 12.1.4.3.1 Deals 471 12.1.4.4 MnM view 471 12.1.4.4.1 Key strengths 471 12.1.4.4.2 Strategic choices 472 12.1.4.4.3 Weaknesses & competitive threats 472 12.1.5 THERMO FISHER SCIENTIFIC INC. 473 12.1.5.1 Business overview 473 12.1.5.2 Products/Services offered 474 12.1.5.3 MnM view 478 12.1.5.3.1 Key strengths 478 12.1.5.3.2 Strategic choices 478 12.1.5.3.3 Weaknesses & competitive threats 478 12.1.6 MERCK KGAA 479 12.1.6.1 Business overview 479 12.1.6.2 Products/Services offered 480 12.1.7 BIO-RAD LABORATORIES, INC. 489 12.1.7.1 Business overview 489 12.1.7.2 Products/Services offered 490 12.1.8 BIO-TECHNE 494 12.1.8.1 Business overview 494 12.1.8.2 Products/Services offered 495 12.1.8.3 Recent developments 498 12.1.8.3.1 Deals 498 12.1.8.3.2 Other developments 499 12.1.9 BECTON, DICKINSON AND COMPANY (BD) 500 12.1.9.1 Business overview 500 12.1.9.2 Products/Services offered 501 12.1.10 TAKARA BIO INC. 507 12.1.10.1 Business overview 507 12.1.10.2 Products/Services offered 508 12.1.11 ENZO BIOCHEM INC. 514 12.1.11.1 Business overview 514 12.1.11.2 Products/Services offered 515 12.1.11.3 Recent developments 517 12.1.11.3.1 Expansions 517 12.1.12 SINO BIOLOGICAL, INC. 518 12.1.12.1 Business overview 518 12.1.12.2 Products/Services offered 518 12.1.13 SAKURA FINETEK JAPAN CO., LTD. 520 12.1.13.1 Business overview 520 12.1.13.2 Products/Services offered 520 12.1.13.3 Recent developments 523 12.1.13.3.1 Product launches 523 12.1.13.3.2 Deals 524 12.1.14 CELL SIGNALING TECHNOLOGY, INC. 525 12.1.14.1 Business overview 525 12.1.14.2 Products/Services offered 525 12.1.14.3 Recent developments 529 12.1.14.3.1 Deals 529 12.1.15 BIO SB 530 12.1.15.1 Business overview 530 12.1.15.2 Products/Services offered 530 12.1.15.3 Recent developments 535 12.1.15.3.1 Product launches 535 12.1.16 MILTENYI BIOTEC 536 12.1.16.1 Business overview 536 12.1.16.2 Products/Services offered 536 12.1.17 ORIGENE TECHNOLOGIES, INC. 539 12.1.17.1 Business overview 539 12.1.17.2 Products/Services offered 539 12.2 OTHER PLAYERS 544 12.2.1 EAGLEBIO 544 12.2.2 BIOCARE MEDICAL, LLC 545 12.2.3 ELABSCIENCE 546 12.2.4 BIOGENEX 548 12.2.5 DIAGNOSTIC BIOSYSTEMS INC. 549 12.2.6 HISTO-LINE LABORATORIES 551 12.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 553 12.2.8 CANDOR BIOSCIENCE GMBH 554 12.2.9 GENEMED BIOTECHNOLOGIES, INC. 555 13 APPENDIX 556 13.1 DISCUSSION GUIDE 556 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 560 13.3 CUSTOMIZATION OPTIONS 562 13.4 RELATED REPORTS 562 13.5 AUTHOR DETAILS 563
圖表清單 List of Tables & Figures
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS 53 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 66 TABLE 3 IMMUNOHISTOCHEMISTRY MARKET: RISK ANALYSIS 69 TABLE 4 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 84 TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES 85 TABLE 6 AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION) 93 TABLE 7 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION) 95 TABLE 8 AVERAGE SELLING PRICE TREND OF KITS, BY REGION, 2022–2024 (USD MILLION) 96 TABLE 9 AVERAGE SELLING PRICE TREND OF ANTIBODIES, BY REGION, 2022–2024 (USD MILLION) 96 TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 100 TABLE 11 LIST OF KEY PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2023–2025 102 TABLE 12 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 103 TABLE 13 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 104 TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE IN ECOSYSTEM 108 TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES 109 TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 111 TABLE 17 KEY BUYING CRITERIA FOR MAJOR END USERS 112 TABLE 18 IMMUNOHISTOCHEMISTRY MARKET: TARIFF DATA FOR HS CODES 9027.50, 3822.00, AND 3507 114 TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 115 TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 117 TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 119 TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 120 TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 120 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 122 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123 TABLE 27 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124 TABLE 28 LIST OF KEY CONFERENCES & EVENTS IN IMMUNOHISTOCHEMISTRY MARKET, JANUARY 2025–DECEMBER 2026 125 TABLE 29 INVESTMENT & FUNDING SCENARIO OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET, 2022−2025 126 TABLE 30 KEY PLAYERS IMPLEMENTING AI/GEN AI IN IMMUNOCHEMISTRY MARKET 129 TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES 130 TABLE 32 KEY PRODUCT-RELATED TARIFF: LIVE ANIMALS, PRODUCTS OF ANIMAL ORIGIN, AND MISCELLANEOUS CHEMICAL PRODUCTS 131 TABLE 33 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 132 TABLE 34 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 136 TABLE 35 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 36 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 37 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 38 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 39 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 40 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 41 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 42 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 43 PRIMARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 44 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 45 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 46 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 47 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 48 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 49 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 50 SECONDARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 51 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 52 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 53 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 54 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 55 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 56 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 57 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 146 TABLE 58 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 59 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 60 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 61 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 62 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 63 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 64 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 65 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 66 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 67 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 68 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 69 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 70 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 71 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 72 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 73 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 74 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 75 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 76 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 77 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 78 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 79 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 154 TABLE 80 CLASS I/II ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 81 NORTH AMERICA: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 82 EUROPE: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 83 ASIA PACIFIC: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 84 LATIN AMERICA: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 85 MIDDLE EAST: CLASS I/II ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 86 GCC COUNTRIES: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 87 CLASS III ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 88 NORTH AMERICA: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 89 EUROPE: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 90 ASIA PACIFIC: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 91 LATIN AMERICA: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 92 MIDDLE EAST: CLASS III ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 93 GCC COUNTRIES: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 94 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 95 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 96 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 97 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 98 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 99 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 100 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 101 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 102 BLOCKING SERA & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 103 NORTH AMERICA: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 104 EUROPE: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 105 ASIA PACIFIC: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 106 LATIN AMERICA: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 107 MIDDLE EAST: BLOCKING SERA & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 108 GCC COUNTRIES: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 109 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 110 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 111 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 112 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 113 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 114 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 115 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 116 FIXATION REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 117 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 118 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 119 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 120 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 121 MIDDLE EAST: FIXATION REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 122 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 123 ORGANIC SOLVENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 124 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 125 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 126 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 127 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 128 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 129 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 130 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 131 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 132 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 133 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 134 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 135 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 136 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 137 DILUENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 138 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 139 EUROPE: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 140 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 141 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 142 MIDDLE EAST: DILUENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 143 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 144 OTHER REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 145 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 146 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 147 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 148 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 149 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 150 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 151 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 152 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 153 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 154 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 155 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 156 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 157 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 158 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 159 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 160 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 161 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 162 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 163 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 164 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 165 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 166 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 167 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 168 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 169 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 170 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 171 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 172 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 173 IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 174 IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 175 NORTH AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 176 EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 177 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 178 LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 179 MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 180 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 181 IHC STAINERS MARKET, BY VOLUME, 2023–2030 (UNITS) 196 TABLE 182 IHC STAINERS MARKET, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 183 NORTH AMERICA: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 184 EUROPE: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 185 ASIA PACIFIC: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 186 LATIN AMERICA: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 187 MIDDLE EAST: IHC STAINERS MARKET, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 188 GCC COUNTRIES: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 189 SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 190 SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 199 TABLE 191 NORTH AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 192 EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 193 ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 194 LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 195 MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 196 GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 197 TISSUE PROCESSORS MARKET, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 198 NORTH AMERICA: TISSUE PROCESSORS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 199 EUROPE: TISSUE PROCESSORS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 200 ASIA PACIFIC: TISSUE PROCESSORS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 201 LATIN AMERICA: TISSUE PROCESSORS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 202 MIDDLE EAST: TISSUE PROCESSORS MARKET, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 203 GCC COUNTRIES: TISSUE PROCESSORS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 204 MICROTOMES MARKET, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 205 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 206 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 207 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 208 LATIN AMERICA: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 209 MIDDLE EAST: MICROTOMES MARKET, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 210 GCC COUNTRIES: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 211 OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 212 NORTH AMERICA: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 213 EUROPE: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 214 ASIA PACIFIC: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 215 LATIN AMERICA: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 216 MIDDLE EAST: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 217 GCC COUNTRIES: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 218 IMAGE ANALYSIS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 219 NORTH AMERICA: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 220 EUROPE: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 221 ASIA PACIFIC: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 222 LATIN AMERICA: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 223 MIDDLE EAST: IMAGE ANALYSIS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 212 TABLE 224 GCC COUNTRIES: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 225 IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 215 TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 232 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 234 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 218 TABLE 235 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 236 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 237 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 238 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 239 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 240 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 241 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 220 TABLE 242 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 243 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 244 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 245 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 246 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 222 TABLE 247 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 248 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 223 TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 251 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 225 TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 255 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 226 TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 228 TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 228 TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 228 TABLE 262 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 229 TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 229 TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 231 TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 269 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 232 TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 233 TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 233 TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 234 TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 276 OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 235 TABLE 277 NORTH AMERICA: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 278 EUROPE: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 279 ASIA PACIFIC: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 280 LATIN AMERICA: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 281 MIDDLE EAST: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 237 TABLE 282 GCC COUNTRIES: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 283 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 284 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 238 TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 240 TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 291 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2023–2030 (USD MILLION) 241 TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2023–2030 (USD MILLION) 243 TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 298 OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 244 TABLE 299 NORTH AMERICA: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 244 TABLE 300 EUROPE: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 301 ASIA PACIFIC: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 302 LATIN AMERICA: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 303 MIDDLE EAST: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 246 TABLE 304 GCC COUNTRIES: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 305 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 247 TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 247 TABLE 307 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 248 TABLE 308 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 248 TABLE 309 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 249 TABLE 310 MIDDLE EAST: IIMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 249 TABLE 311 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 249 TABLE 312 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 313 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 252 TABLE 314 NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 315 EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 316 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 317 LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 318 MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 253 TABLE 319 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 320 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 255 TABLE 321 NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 322 EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 256 TABLE 323 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 256 TABLE 324 LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 325 MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 257 TABLE 326 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 327 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 258 TABLE 328 NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 258 TABLE 329 EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 259 TABLE 330 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 259 TABLE 331 LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 260 TABLE 332 MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 260 TABLE 333 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 260 TABLE 334 IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 262 TABLE 335 IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 263 TABLE 336 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 263 TABLE 337 EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 263 TABLE 338 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 264 TABLE 339 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 264 TABLE 340 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 264 TABLE 341 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 265 TABLE 342 IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2023–2030 (USD MILLION) 266 TABLE 343 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 266 TABLE 344 EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 266 TABLE 345 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 267 TABLE 346 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 267 TABLE 347 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2023–2030 (USD MILLION) 267 TABLE 348 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 268 TABLE 349 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2023–2030 (USD MILLION) 270 TABLE 350 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 272 TABLE 351 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 272 TABLE 352 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 353 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 273 TABLE 354 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 273 TABLE 355 NORTH AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 356 NORTH AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 357 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 358 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 359 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 275 TABLE 360 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 361 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 362 NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 363 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 364 NORTH AMERICA: KEY MACROINDICATORS 277 TABLE 365 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 278 TABLE 366 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 279 TABLE 367 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 368 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 280 TABLE 369 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 280 TABLE 370 US: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 371 US: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 372 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 373 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 374 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 375 US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 376 US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 377 US: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 378 US: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 379 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 284 TABLE 380 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 381 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 284 TABLE 382 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 285 TABLE 383 CANADA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 384 CANADA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 385 CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 386 CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 387 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 388 CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 389 CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 390 CANADA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 287 TABLE 391 CANADA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 392 EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 288 TABLE 393 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 289 TABLE 394 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 289 TABLE 395 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 396 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 290 TABLE 397 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 290 TABLE 398 EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 399 EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 400 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 401 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 402 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 292 TABLE 403 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 404 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 405 EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 293 TABLE 406 EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 293 TABLE 407 EUROPE: KEY MACROINDICATORS 294 TABLE 408 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 295 TABLE 409 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 410 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 296 TABLE 411 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 296 TABLE 412 GERMANY: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 413 GERMANY: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 414 GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 415 GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 416 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 298 TABLE 417 GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 418 GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 419 GERMANY: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 420 GERMANY: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 421 UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 300 TABLE 422 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 423 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 301 TABLE 424 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 301 TABLE 425 UK: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 426 UK: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 427 UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 428 UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 429 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 303 TABLE 430 UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 431 UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 432 UK: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 304 TABLE 433 UK: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 304 TABLE 434 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 305 TABLE 435 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 306 TABLE 436 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 306 TABLE 437 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 306 TABLE 438 FRANCE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 439 FRANCE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 440 FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 441 FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 442 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 308 TABLE 443 FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 444 FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 445 FRANCE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 309 TABLE 446 FRANCE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 447 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 310 TABLE 448 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 449 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 311 TABLE 450 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 311 TABLE 451 ITALY: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 452 ITALY: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 453 ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 454 ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 455 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 313 TABLE 456 ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 457 ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 458 ITALY: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 314 TABLE 459 ITALY: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 315 TABLE 460 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 315 TABLE 461 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 462 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 316 TABLE 463 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 316 TABLE 464 SPAIN: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 465 SPAIN: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 466 SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 467 SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 468 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 318 TABLE 469 SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 470 SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 471 SPAIN: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 472 SPAIN: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 320 TABLE 473 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 320 TABLE 474 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 475 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 321 TABLE 476 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 321 TABLE 477 REST OF EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 478 REST OF EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 479 REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 480 REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 481 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 323 TABLE 482 REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 483 REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 484 REST OF EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 324 TABLE 485 REST OF EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 325 TABLE 486 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 327 TABLE 487 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 327 TABLE 488 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 489 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 328 TABLE 490 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 328 TABLE 491 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 492 ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 493 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 494 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 495 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 330 TABLE 496 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 497 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 498 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 331 TABLE 499 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 331 TABLE 500 ASIA PACIFIC: KEY MACROINDICATORS 332 TABLE 501 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 333 TABLE 502 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 503 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 334 TABLE 504 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 334 TABLE 505 CHINA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 506 CHINA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 507 CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 508 CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 509 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 336 TABLE 510 CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 511 CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 512 CHINA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 337 TABLE 513 CHINA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 338 TABLE 514 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 339 TABLE 515 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 516 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 339 TABLE 517 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 340 TABLE 518 JAPAN: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 519 JAPAN: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 520 JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 521 JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 522 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 341 TABLE 523 JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 342 TABLE 524 JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 342 TABLE 525 JAPAN: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 342 TABLE 526 JAPAN: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 343 TABLE 527 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 344 TABLE 528 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 529 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 344 TABLE 530 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 345 TABLE 531 INDIA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 532 INDIA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 533 INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 534 INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 535 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 346 TABLE 536 INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 537 INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 538 INDIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 347 TABLE 539 INDIA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 348 TABLE 540 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 349 TABLE 541 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 349 TABLE 542 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 349 TABLE 543 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 350 TABLE 544 AUSTRALIA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 545 AUSTRALIA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 546 AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 547 AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 548 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 351 TABLE 549 AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 550 AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 551 AUSTRALIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 352 TABLE 552 AUSTRALIA: IMMUNOHISTOCHEMISTRY SEERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 353 TABLE 553 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 354 TABLE 554 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 354 TABLE 555 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 354 TABLE 556 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 355 TABLE 557 SOUTH KOREA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 355 TABLE 558 SOUTH KOREA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 355 TABLE 559 SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 356 TABLE 560 SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 356 TABLE 561 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 356 TABLE 562 SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 563 SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 564 SOUTH KOREA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 357 TABLE 565 SOUTH KOREA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 358 TABLE 566 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 358 TABLE 567 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 359 TABLE 568 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 359 TABLE 569 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 359 TABLE 570 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 360 TABLE 571 REST OF ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 360 TABLE 572 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 573 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 574 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 361 TABLE 575 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 576 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 577 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 362 TABLE 578 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 363 TABLE 579 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 363 TABLE 580 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 364 TABLE 581 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 364 TABLE 582 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 364 TABLE 583 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 365 TABLE 584 LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 365 TABLE 585 LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 365 TABLE 586 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 587 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 588 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 366 TABLE 589 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 590 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 591 LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 367 TABLE 592 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 368 TABLE 593 LATIN AMERICA: KEY MACROINDICATORS 369 TABLE 594 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 370 TABLE 595 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 370 TABLE 596 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 370 TABLE 597 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 371 TABLE 598 BRAZIL: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 599 BRAZIL: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 600 BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 601 BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 602 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 372 TABLE 603 BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 373 TABLE 604 BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 373 TABLE 605 BRAZIL: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 373 TABLE 606 BRAZIL: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 374 TABLE 607 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 374 TABLE 608 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 375 TABLE 609 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 375 TABLE 610 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 375 TABLE 611 MEXICO: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 612 MEXICO: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 613 MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 614 MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 615 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 377 TABLE 616 MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 378 TABLE 617 MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 378 TABLE 618 MEXICO: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 378 TABLE 619 MEXICO: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 379 TABLE 620 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 379 TABLE 621 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 380 TABLE 622 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 380 TABLE 623 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 380 TABLE 624 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 625 REST OF LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 626 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 627 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 628 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 382 TABLE 629 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 383 TABLE 630 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 383 TABLE 631 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 383 TABLE 632 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 384 TABLE 633 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2023–2030 (USD MILLION) 384 TABLE 634 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 385 TABLE 635 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 385 TABLE 636 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 385 TABLE 637 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 386 TABLE 638 MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 386 TABLE 639 MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 386 TABLE 640 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 387 TABLE 641 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 387 TABLE 642 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 387 TABLE 643 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 388 TABLE 644 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 388 TABLE 645 MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 388 TABLE 646 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 389 TABLE 647 MIDDLE EAST: KEY MACROINDICATORS 390 TABLE 648 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 390 TABLE 649 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 391 TABLE 650 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 391 TABLE 651 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 391 TABLE 652 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 392 TABLE 653 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 392 TABLE 654 GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 392 TABLE 655 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 393 TABLE 656 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 393 TABLE 657 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 393 TABLE 658 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 394 TABLE 659 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 394 TABLE 660 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 394 TABLE 661 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 395 TABLE 662 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 395 TABLE 663 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 396 TABLE 664 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 396 TABLE 665 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 396 TABLE 666 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 397 TABLE 667 KINGDOM OF SAUDI ARABIA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 397 TABLE 668 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 398 TABLE 669 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 398 TABLE 670 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 398 TABLE 671 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 399 TABLE 672 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 399 TABLE 673 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 399 TABLE 674 KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 400 TABLE 675 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 400 TABLE 676 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 401 TABLE 677 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 401 TABLE 678 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 401 TABLE 679 UAE: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 402 TABLE 680 UAE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 402 TABLE 681 UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 403 TABLE 682 UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 403 TABLE 683 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 403 TABLE 684 UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 404 TABLE 685 UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 404 TABLE 686 UAE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 404 TABLE 687 UAE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 405 TABLE 688 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 405 TABLE 689 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 406 TABLE 690 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 406 TABLE 691 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 406 TABLE 692 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 407 TABLE 693 REST OF GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 407 TABLE 694 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 408 TABLE 695 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 408 TABLE 696 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 409 TABLE 697 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 409 TABLE 698 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 409 TABLE 699 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 410 TABLE 700 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 410 TABLE 701 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 411 TABLE 702 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 411 TABLE 703 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 411 TABLE 704 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 412 TABLE 705 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 412 TABLE 706 REST OF MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 412 TABLE 707 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 413 TABLE 708 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 413 TABLE 709 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 413 TABLE 710 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 414 TABLE 711 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 414 TABLE 712 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 414 TABLE 713 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 415 TABLE 714 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 415   TABLE 715 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 416 TABLE 716 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION) 416 TABLE 717 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION) 416 TABLE 718 AFRICA: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 417 TABLE 719 AFRICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 417 TABLE 720 AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 418 TABLE 721 AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 418 TABLE 722 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 418 TABLE 723 AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 419 TABLE 724 AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 419 TABLE 725 AFRICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 419 TABLE 726 AFRICA: KEY MACROINDICATORS 421 TABLE 727 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET 422 TABLE 728 IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION 425 TABLE 729 IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT 429 TABLE 730 IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT 430 TABLE 731 IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT 431 TABLE 732 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY STARTUP/ SME PLAYERS 434 TABLE 733 IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING AND REGION 435 TABLE 734 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 438 TABLE 735 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2022–AUGUST 2025 439 TABLE 736 IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 439 TABLE 737 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 440 TABLE 738 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 441 TABLE 739 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 442 TABLE 740 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 446 TABLE 741 DANAHER CORPORATION: COMPANY OVERVIEW 450 TABLE 742 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 451   TABLE 743 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 455 TABLE 744 DANAHER CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 456 TABLE 745 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 457 TABLE 746 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 458 TABLE 747 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 462 TABLE 748 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–AUGUST 2025 463 TABLE 749 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 463 TABLE 750 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 465 TABLE 751 PHC HOLDINGS CORPORATION: PRODUCTS/SERVICES OFFERED 466 TABLE 752 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 471 TABLE 753 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 473 TABLE 754 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 474 TABLE 755 MERCK KGAA: COMPANY OVERVIEW 479 TABLE 756 MERCK KGAA: PRODUCTS/SERVICES OFFERED 480 TABLE 757 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 489 TABLE 758 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 490 TABLE 759 BIO-TECHNE: COMPANY OVERVIEW 494 TABLE 760 BIO-TECHNE: PRODUCTS/SERVICES OFFERED 495 TABLE 761 BIO-TECHNE: DEALS, JANUARY 2022–AUGUST 2025 498 TABLE 762 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 499 TABLE 763 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 500 TABLE 764 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS/SERVICES OFFERED 501 TABLE 765 TAKARA BIO INC.: COMPANY OVERVIEW 507 TABLE 766 TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED 508 TABLE 767 ENZO BIOCHEM INC.: COMPANY OVERVIEW 514 TABLE 768 ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED 515 TABLE 769 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 517 TABLE 770 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 518 TABLE 771 SINO BIOLOGICAL, INC.: PRODUCTS/SERVICES OFFERED 518 TABLE 772 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW 520 TABLE 773 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SERVICES OFFERED 520 TABLE 774 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 523 TABLE 775 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2022–AUGUST 2025 524 TABLE 776 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 525 TABLE 777 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED 525 TABLE 778 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2022–AUGUST 2025 529 TABLE 779 BIO SB: COMPANY OVERVIEW 530 TABLE 780 BIO SB: PRODUCTS/SERVICES OFFERED 530   TABLE 781 BIO SB: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 535 TABLE 782 MILTENYI BIOTEC: COMPANY OVERVIEW 536 TABLE 783 MILTENYI BIOTEC: PRODUCTS/SERVICES OFFERED 536 TABLE 784 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 539 TABLE 785 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 539 TABLE 786 EAGLEBIO: COMPANY OVERVIEW 544 TABLE 787 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 545 TABLE 788 ELABSCIENCE: COMPANY OVERVIEW 546 TABLE 789 BIOGENEX: COMPANY OVERVIEW 548 TABLE 790 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW 549 TABLE 791 HISTO-LINE LABORATORIES: COMPANY OVERVIEW 551 TABLE 792 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW 553 TABLE 793 CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW 554 TABLE 794 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 555 FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION & REGIONAL SCOPE 52 FIGURE 2 IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED 54 FIGURE 3 IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN 57 FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 59 FIGURE 5 IMMUNOHISTOCHEMISTRY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 60 FIGURE 6 IMMUNOHISTOCHEMISTRY MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024 61 FIGURE 7 COMPANY REVENUE ANALYSIS: ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD. (2024) 62 FIGURE 8 IMMUNOHISTOCHEMISTRY MARKET: KEY INSIGHTS FROM PRIMARIES 63 FIGURE 9 IMMUNOHISTOCHEMISTRY SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 64 FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTIONS 65 FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET: DATA TRIANGULATION 67 FIGURE 12 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 70 FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 71 FIGURE 14 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 71 FIGURE 15 IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 72 FIGURE 16 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL ANALYSIS 73 FIGURE 17 GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION) 76 FIGURE 18 INCREASING ADOPTION OF COMPANION DIAGNOSTICS IN IMMUNOHISTOCHEMISTRY TO PROPEL MARKET GROWTH 77 FIGURE 19 US AND DIAGNOSTIC APPLICATIONS COMMANDED LARGEST NORTH AMERICAN IMMUNOHISTOCHEMISTRY MARKET SHARE IN 2024 78 FIGURE 20 HOSPITALS & DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 78 FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 79 FIGURE 22 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 83 FIGURE 23 SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015–2024) 90 FIGURE 24 IMMUNOHISTOCHEMISTRY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 92 FIGURE 25 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 94 FIGURE 26 AVERAGE SELLING PRICE OF KITS, BY KEY PLAYER, 2024 (USD) 94 FIGURE 27 AVERAGE SELLING PRICE OF ANTIBODIES, BY KEY PLAYER, 2024 (USD) 95 FIGURE 28 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION) 96 FIGURE 29 AVERAGE SELLING PRICE OF KITS, BY REGION, 2024 (USD MILLION) 97 FIGURE 30 AVERAGE SELLING PRICE OF ANTIBODIES, BY REGION, 2024 (USD MILLION) 97 FIGURE 31 PATENT APPLICATIONS IN IMMUNOHISTOCHEMISTRY MARKET, JANUARY 2014-DECEMBER 2024 101 FIGURE 32 IMMUNOHISTOCHEMISTRY MARKET: VALUE CHAIN ANALYSIS 105 FIGURE 33 IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS 107 FIGURE 34 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS 109 FIGURE 35 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 111 FIGURE 36 KEY BUYING CRITERIA FOR MAJOR END USERS 112 FIGURE 37 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 116 FIGURE 38 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 117 FIGURE 39 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 118 FIGURE 40 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 119 FIGURE 41 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 121 FIGURE 42 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 122 FIGURE 43 FUNDING AND NUMBER OF DEALS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2025 (USD MILLION) 127 FIGURE 44 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET 128 FIGURE 45 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 271 FIGURE 46 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 326 FIGURE 47 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2024 (USD MILLION) 424 FIGURE 48 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2024) 425 FIGURE 49 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 428 FIGURE 50 IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT 429 FIGURE 51 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 433 FIGURE 52 EV/EBITDA OF KEY VENDORS 436 FIGURE 53 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 436 FIGURE 54 IMMUNOHISTOCHEMISTRY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 437 FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 442 FIGURE 56 DANAHER CORPORATION: COMPANY SNAPSHOT 451 FIGURE 57 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 458 FIGURE 58 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT 466 FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 474 FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT 480 FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 490 FIGURE 62 BIO-TECHNE: COMPANY SNAPSHOT 495 FIGURE 63 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 501 FIGURE 64 TAKARA BIO INC.: COMPANY SNAPSHOT 508 FIGURE 65 ENZO BIOCHEM INC.: COMPANY SNAPSHOT 514

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們